Philippines Pharmaceutical Market Sees Growth Driven by Generic Drugs

The pharmaceutical industry in the Philippines is experiencing significant growth, with the market valued at USD 3.36 billion in 2025. Projections indicate a further rise to USD 3.91 billion by 2034, driven by a population exceeding 111 million, government healthcare initiatives, and an increasing prevalence of chronic diseases.

A key trend is the surge in the adoption of generic drugs, which now account for approximately 76% of the total pharmaceutical market by volume. This shift is supported by government policies such as the "Cheaper Medicines Act," promoting generic use and bulk procurement. The Universal Health Care (UHC) Act of 2019 also expands insurance coverage to all Filipinos, increasing demand and accessibility of medicines.

The market features competition from both multinational corporations and domestic manufacturers. United Laboratories (Unilab) is a major local player offering a range of branded and generic medications. Multinational companies like AstraZeneca are also investing, with AstraZeneca committing over PHP 7 billion between 2026 and 2028 to support the country's healthcare innovation landscape.

Regulatory oversight is managed by the Philippines Food and Drug Administration (FDA). The "Generics Act of 1988" mandates physicians to prescribe by generic name, empowering patients to choose more affordable options. The UHC Act aims to guarantee equitable access to quality and affordable healthcare goods and services for all citizens.